KR102993656B1 - 요법에 사용하기 위한 parp14의 표적화된 단백질 분해 - Google Patents
요법에 사용하기 위한 parp14의 표적화된 단백질 분해Info
- Publication number
- KR102993656B1 KR102993656B1 KR1020217041538A KR20217041538A KR102993656B1 KR 102993656 B1 KR102993656 B1 KR 102993656B1 KR 1020217041538 A KR1020217041538 A KR 1020217041538A KR 20217041538 A KR20217041538 A KR 20217041538A KR 102993656 B1 KR102993656 B1 KR 102993656B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- thio
- quinazolin
- delete delete
- pyran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863357P | 2019-06-19 | 2019-06-19 | |
| US62/863,357 | 2019-06-19 | ||
| PCT/US2020/038377 WO2020257416A1 (en) | 2019-06-19 | 2020-06-18 | Targeted protein degradation of parp14 for use in therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220024098A KR20220024098A (ko) | 2022-03-03 |
| KR102993656B1 true KR102993656B1 (ko) | 2026-07-23 |
Family
ID=71527971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217041538A Active KR102993656B1 (ko) | 2019-06-19 | 2020-06-18 | 요법에 사용하기 위한 parp14의 표적화된 단백질 분해 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220388985A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3986887A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022537349A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102993656B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN114206853A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020296063B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021025645A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3142002A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA56513A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202112980TA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020257416A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3728207T (pt) | 2017-12-21 | 2023-03-14 | Ribon Therapeutics Inc | Quinazolinonas como inibidores de parp14 |
| WO2022150667A1 (en) * | 2021-01-08 | 2022-07-14 | The Board Of Regents Of The University Of Texas System | Nimbolide analogs and methods of use thereof |
| JP2024505228A (ja) * | 2021-01-29 | 2024-02-05 | ライボン・セラピューティクス・インコーポレイテッド | 炎症性疾患を処置する方法 |
| CN114890989B (zh) * | 2022-05-25 | 2024-03-22 | 广东晨康生物科技有限公司 | 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用 |
| CN117229224B (zh) * | 2022-06-07 | 2026-05-08 | 中国药科大学 | 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用 |
| CN119923391A (zh) * | 2022-07-29 | 2025-05-02 | 艾伯维新加坡运营私人有限公司 | 在疗法中使用的parp14的靶向蛋白降解 |
| CN119923394A (zh) * | 2022-07-29 | 2025-05-02 | 艾伯维新加坡运营私人有限公司 | 在疗法中使用的parp14的靶向蛋白降解 |
| CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| WO2024251205A1 (zh) * | 2023-06-06 | 2024-12-12 | 西藏海思科制药有限公司 | 一种喹唑啉酮衍生物及其在医药上的应用 |
| CN116813640A (zh) * | 2023-06-29 | 2023-09-29 | 成都金瑞基业生物科技有限公司 | 一类抑制并降解parp的化合物及应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019014429A1 (en) | 2017-07-12 | 2019-01-17 | Dana-Farber Cancer Institute, Inc. | COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN |
| US20190194174A1 (en) | 2017-12-21 | 2019-06-27 | Ribon Therapeutics Inc. | Quinazolinones as parp14 inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102438072B1 (ko) * | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| EP2890696A1 (en) * | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
| SMT202000133T1 (it) * | 2014-04-23 | 2020-05-08 | Incyte Corp | 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| MX2019005007A (es) * | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| EP4119552A1 (en) * | 2017-02-08 | 2023-01-18 | Dana-Farber Cancer Institute, Inc. | Regulating chimeric antigen receptors |
-
2020
- 2020-06-18 BR BR112021025645A patent/BR112021025645A2/pt unknown
- 2020-06-18 CN CN202080044704.2A patent/CN114206853A/zh active Pending
- 2020-06-18 MA MA056513A patent/MA56513A/fr unknown
- 2020-06-18 KR KR1020217041538A patent/KR102993656B1/ko active Active
- 2020-06-18 EP EP20737701.1A patent/EP3986887A1/en active Pending
- 2020-06-18 SG SG11202112980TA patent/SG11202112980TA/en unknown
- 2020-06-18 CN CN202510536711.9A patent/CN120398840A/zh active Pending
- 2020-06-18 WO PCT/US2020/038377 patent/WO2020257416A1/en not_active Ceased
- 2020-06-18 JP JP2021575326A patent/JP2022537349A/ja active Pending
- 2020-06-18 US US17/619,459 patent/US20220388985A1/en not_active Abandoned
- 2020-06-18 AU AU2020296063A patent/AU2020296063B2/en active Active
- 2020-06-18 CA CA3142002A patent/CA3142002A1/en active Pending
-
2025
- 2025-04-02 JP JP2025061199A patent/JP7844707B2/ja active Active
- 2025-05-22 US US19/216,120 patent/US20260125362A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019014429A1 (en) | 2017-07-12 | 2019-01-17 | Dana-Farber Cancer Institute, Inc. | COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN |
| US20190194174A1 (en) | 2017-12-21 | 2019-06-27 | Ribon Therapeutics Inc. | Quinazolinones as parp14 inhibitors |
Non-Patent Citations (2)
| Title |
|---|
| Mini-Reviews in Medicinal Chemistry, 2018, Vol. 18, No. 19, pp. 1659-1669 |
| Nature Biotechnology, 2012, Vol. 30, No. 3, pp. 283-289 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114206853A (zh) | 2022-03-18 |
| JP2025102917A (ja) | 2025-07-08 |
| EP3986887A1 (en) | 2022-04-27 |
| SG11202112980TA (en) | 2021-12-30 |
| WO2020257416A1 (en) | 2020-12-24 |
| BR112021025645A2 (pt) | 2022-02-01 |
| JP7844707B2 (ja) | 2026-04-13 |
| CN120398840A (zh) | 2025-08-01 |
| KR20220024098A (ko) | 2022-03-03 |
| CA3142002A1 (en) | 2020-12-24 |
| JP2022537349A (ja) | 2022-08-25 |
| AU2020296063A1 (en) | 2021-12-23 |
| AU2020296063B2 (en) | 2026-01-29 |
| MA56513A (fr) | 2022-04-27 |
| US20260125362A1 (en) | 2026-05-07 |
| US20220388985A1 (en) | 2022-12-08 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R19-X000 | Request for party data change rejected |
St.27 status event code: A-3-3-R10-R19-oth-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |